Eli Lilly and Co. is investing $3 billion to expand its recently acquired manufacturing facility in Kenosha County, WI. This investment will extend the company’s global parenteral product manufacturing network to support its diabetes, obesity and future pipeline medicines across therapeutic areas. Lilly expects to add 750 highly skilled jobs to the current 100-plus workforce at this location.
 
The expanded facility will focus on manufacturing injectable medicines, device assembly and packaging for medicines across multiple therapeutic areas.
 
Lilly will use advanced automation, including guided vehicles, robotics and production equipment, to accelerate medicine production. Digital automation will be used throughout the site to help accelerate processes and increase accuracy. New jobs at the site will include operators, technicians, engineers and scientists.

The company plans to start construction next year. Since 2020, Lilly has invested more than $23 billion to construct, expand and acquire manufacturing sites worldwide.

“Today’s announcement represents our single largest U.S. manufacturing investment outside our home state of Indiana and will add to our ability to expand capacity to make both our existing and future pipeline of medicines right here in the Midwest,” said Edgardo Hernandez, executive vice president and president of Lilly Manufacturing Operations. “We look forward to bringing high-wage, advanced manufacturing, engineering and science jobs to people in Wisconsin, a state that is becoming a critical geography in our global manufacturing operations.”